Core Insights - Acentra Health has appointed Deborah Ricci as Executive Vice President and Chief Financial Officer, aiming to enhance its financial leadership during a critical phase of growth and transformation [1][3]. Company Overview - Acentra Health is a technology and health solutions company focused on improving health outcomes for government and commercial clients, leveraging public sector knowledge, clinical expertise, and technological innovation [5]. - The company is backed by Carlyle, a global investment firm, indicating strong financial support and potential for growth [5]. Leadership Background - Deborah Ricci joins Acentra Health from Guidehouse Inc., where she served as Partner and Chief Financial & Administrative Officer, overseeing finance, accounting, quality, risk, security, and facilities [2]. - Ricci has extensive experience in senior finance leadership roles, including CFO positions at Constellis, Centerra Group, and A-T Solutions, and began her career as a certified public accountant with KPMG [2]. Strategic Vision - The CEO of Acentra Health, Todd Stottlemyer, emphasized Ricci's proven track record in building scalable financial systems and leading organizations through significant changes, aligning her expertise with the company's growth and transformation plans [3]. - Ricci expressed her commitment to Acentra Health's mission-driven work and long-term value creation, indicating a strong alignment with the company's strategic goals [4]. Additional Roles - Ricci currently serves as Chair of the Finance and Audit Committee for Draken International Inc. and is an advisory board member for Cydecor, showcasing her active involvement in the finance sector [4]. - She holds an MBA from the University of Pittsburgh School of Business and a bachelor's degree from Bentley University, highlighting her strong educational background [4].

Core Viewpoint - The rise in Japanese government bond yields and the depreciation of the yen are seen as positive signs for Japan's economy, indicating a potential exit from decades of deflation, despite some criticism [1] Group 1: Economic Indicators - Japanese policymakers have been gradually raising interest rates while effectively suppressing the yen's exchange rate [1] - A more competitive exchange rate is expected to enhance domestic corporate profits [1] Group 2: Expert Commentary - Jason Thomas, the global head of research and investment strategy at Carlyle Group, emphasizes that interest rate normalization should not be a cause for concern for an economy finally emerging from deflation [1] - There is a warning against misinterpreting market signals in the current economic context [1] Group 3: Market Reactions - The continuous depreciation of the yen and the rise in Japanese government bond yields to the highest levels in a generation have raised concerns among some market participants [1]

Group 1 - Carlyle, Chevron, Quantum Capital Group, and International Holding Company are competing for global assets of Russia [1] - The competition highlights the interest of private equity firms and major oil companies in acquiring valuable assets in the current geopolitical climate [1] - The involvement of UAE-based investors indicates a growing trend of Middle Eastern capital seeking opportunities in global markets [1] Group 2 - The strategic moves by these companies may reshape the investment landscape in the energy sector [1] - The competition for Russian assets reflects broader trends in private equity and energy investments amid ongoing global economic shifts [1] - The outcome of this competition could have significant implications for future investment strategies in the region [1]

MCLEAN, Va., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions company dedicated to accelerating better health outcomes for government and commercial clients and the populations they serve, announced today its recognition among Modern Healthcare’s 2025 Best in Business in the Healthcare IT category. The award celebrates organizations that drive innovation, efficiency, and excellence across the healthcare industry. By acknowledging the leading innovators within the industry, ...

Core Viewpoint - The article discusses the acquisition of Tescan by Shimadzu Corporation, highlighting the strategic growth and transformation of Tescan under the ownership of Carlyle Group, which led to approximately 50% outperformance in market growth over three years [1][5]. Group 1: Acquisition Details - Carlyle Group announced the sale of Tescan, a leading manufacturer of electron microscopes, to Shimadzu Corporation for an enterprise value of $850 million [2][4]. - Tescan, established in 1991 and headquartered in Brno, Czech Republic, specializes in scanning electron microscopes, ion beam systems, and advanced scientific analysis instruments [4]. Group 2: Strategic Growth - Since acquiring Tescan in January 2023, Carlyle Group has facilitated a management transition and strategic repositioning focused on the rapidly growing semiconductor and nanotechnology markets [5]. - The three-pillar strategy executed by Carlyle and Tescan's management includes enhancing operational excellence, expanding market share through new product launches, and broadening target markets via product innovation and acquisitions [5]. Group 3: Leadership and Future Outlook - Key executives from Carlyle and Tescan expressed confidence in the company's transformation and its strengthened position in the semiconductor and nanotechnology markets, anticipating continued growth under Shimadzu's ownership [6]. - The complementary nature of Tescan's advanced imaging technologies with Shimadzu's product offerings is expected to enhance strategic expansion in high-growth analytical and semiconductor applications [6].

Leadership Changes - Kurt von Emster transitions from Head of Abingworth Life Sciences to Managing Partner, focusing on clinical co-development investments and supporting venture investments [1] - Dr. Bali Muralidhar is appointed as the new Head of Abingworth Life Sciences and Chief Investment Officer [1] - Travis Wilson joins as Managing Director, concentrating on clinical co-development and life sciences buyout opportunities [1] Company Background - Abingworth is a leading transatlantic life sciences investment firm and part of Carlyle, having invested in over 185 life science companies since 1973 [3] - The firm has facilitated over 50 mergers and acquisitions and more than 75 IPOs [3] - Abingworth's investments are categorized into seed and early-stage, development stage, and clinical co-development [3] Carlyle Overview - Carlyle is a global investment firm with $474 billion in assets under management as of September 30, 2025 [4] - The firm operates across three business segments: Global Private Equity, Global Credit, and Carlyle AlpInvest [4] - Carlyle employs over 2,400 people in 27 offices worldwide [4]

Group 1 - Belmond Ltd., a luxury hotel subsidiary of LVMH, blames a railway company controlled by Carlyle Group for a fatal collision on the railway line to Machu Picchu [1] - The accident occurred on December 30, resulting in one death and several injuries due to Inca Rail's train entering an unauthorized section of the track [1] - Inca Rail is cooperating with authorities in the investigation and has expressed condolences to the victims while urging caution against premature conclusions before the investigation is complete [1]

Core Viewpoint - Medline, a global healthcare company, has successfully completed its IPO, marking the largest IPO in the US for the year, with a market capitalization exceeding $54 billion on its first trading day [4][19]. Company Background - Medline was founded in 1966 by brothers Jim and John Mills, inspired by their grandfather's sewing business [5][17]. - The company initially focused on manufacturing medical supplies and has grown to offer a wide range of products, including surgical gowns, gloves, masks, and disinfectants [6][18]. - Medline was briefly public in 1972 but was privatized five years later, remaining a family-owned business until its recent IPO [5][17]. IPO Details - The IPO raised approximately $6.264 billion by issuing 216 million shares at a price of $29 each, with significant interest from cornerstone investors [6][19]. - Medline's IPO was oversubscribed by more than ten times, highlighting strong market demand [6][19]. - The company achieved a first-day closing price that increased by over 41%, bringing its market value to approximately $54 billion [4][19]. Financial Performance - Medline's revenue has shown consistent growth, with a compound annual growth rate of 18% since its inception, reaching $17.5 billion in 2020 and projected to be $25.5 billion in 2024 [7][21]. - The company reported a net profit of $977 million for the first nine months of 2025, indicating strong financial health [21]. Private Equity Involvement - The company was acquired by a consortium of private equity firms, including Blackstone, Carlyle, and Hellman & Friedman, in 2021, purchasing nearly 80% of the company [9][20]. - Since the acquisition, Medline's revenue has increased by nearly 50%, demonstrating the effectiveness of the private equity firms' management strategies [21]. - The private equity firms are expected to benefit significantly from the IPO, with potential returns estimated in the billions [4][10]. Market Impact - Medline's IPO is noted as the largest private equity-backed IPO in history, reflecting the growing trend of private equity firms taking companies public [20]. - The successful IPO is part of a broader trend, with Blackstone completing multiple IPOs in the recent quarter, indicating a robust exit environment for private equity investments [23].

Silver retreating after hitting an all-time high yesterday. Gold is just below record levels. And the clear breakout today, it's platinum, which my next guest is arguably the strongest commodity in the precious metals complex.Joining us now is Jeff Curry, the chief strategy officer at of energy pathways at Carile Group. Jeff, it's so great to see you. Welcome.>> Hey, Kelly. Great to see you as well. You know, I still thought you had the best encapsulation of what was going on in CO when you said there were ...

MUNICH--(BUSINESS WIRE)--Picus Capital ("Picus†or the "Firm†), a global venture capital firm, today announced the closing of a €150 million preferred equity financing transaction provided by Carlyle AlpInvest, a leading global private markets manager. The transaction provides Picus with significant capital for new investments and supports the continued growth of its existing portfolio of almost 200 companies, including notable investments such as Personio and Enpal. Founded in 2015 as a privat. ...